Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2022-01-31 Capital/Financing Update
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you that Fermenta Biotech Limited ....
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015. It announces the signing of a Binding Term Sheet for real estate development involving the company's property. The content includes details about the agreement, parties involved, and future plans but does not contain any financial statements, quarterly or annual results, or detailed financial analysis. It is essentially an announcement of a corporate development or transaction rather than a financial report or earnings release. The document length is 8419 characters, which is sufficient for a detailed announcement but it is not a report itself. This fits best under Capital/Financing Update (CAP) as it relates to a significant corporate transaction involving property development and potential capital implications. It is not a regulatory filing (RNS) because it specifically relates to a material event under Regulation 30, which is typically classified as a capital/financing update. Therefore, the appropriate classification is CAP with high confidence.
2022-01-31 English
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 at the meeting of the Board of Directors held on January 31, 2022 This is ....
M&A Activity Classification · 95% confidence The document is a detailed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a Composite Scheme of Amalgamation and Arrangement involving Fermenta Biotech Limited and two other companies. It includes specifics about the scheme, shareholding changes, regulatory approvals required, and rationale for the merger. The document is an official announcement of a corporate restructuring event, specifically an amalgamation/merger scheme. It is not a full financial report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. The content aligns with announcements related to merger proposals or takeover bids. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length and detail support a high confidence level.
2022-01-31 English
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you the following: The Company ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015. It announces the licensing of proprietary biocatalytic technology for synthesis of Molnupiravir and supply of enzyme to a subsidiary of Dr. Reddy's Laboratories. The document includes a press release detailing the agreement and the technology. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is an announcement of a material event related to the company's business operations and agreements, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like earnings release, capital update, or management report. The document length is 5599 characters, which is sufficient for a detailed announcement but does not contain financial data or report content. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-01-20 English
Certificate under Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018 for the quarter ended December 31, 2021 ('Period') Pursuant to the provisions of Regulation ....
Regulatory Filings
2022-01-14 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about a scheduled analyst/institutional investor conference call to discuss the company's financial performance for the quarter and half year ended September 30, 2021. It explicitly states it is an intimation of the schedule of a conference call, not the transcript or the financial results themselves. The document is only 1629 characters long and does not contain any financial data or detailed discussion. It is an announcement related to an upcoming event rather than the event content or report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-01-03 English
Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, Company''s Code of Conduct for Prevention of Insider Trading, BSE circular no. LIST/COMP/01/2019-20 ....
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window pursuant to SEBI regulations and company code of conduct for insider trading. It informs about the trading restrictions around the announcement of quarterly financial results but does not contain any financial data, results, or detailed report. The document is short (2679 characters) and serves as an announcement related to regulatory compliance and trading restrictions rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2021-12-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.